Xatral (Alfuzosin) 2.5 mg in the Treatment of BPH

Czech version

Authors: J. Novák
Authors‘ workplace: Urologická klinika VFN, Praha, přednosta prof. MUDr. J. Dvořáček, DrSc
Published in: Prakt. Lék. 2001; (7): 396-399
Category:

Overview

772 patients from 68 urological departments took part in the study with alfuzosin 2.5 mg threetimes daily for treatment symptoms of BPH. The study lasted 3 months. The results andpatients’ quality of life were compared with the IPSS score and AUA symptom score. Adverseevents were minimal. The number of orthostatic hypotension was relatively low (1.8%). Thebenefit of the treatment for the patients with BPH treated with alfuzosin 2.5 mg t.i.d. wasrelatively good with a minimal number of adverse events.

Key words:
NPH - study - alfuzosin.

Full text is not available online.

If interested in a scan of this journal, contact NTO ČLS JEP.